<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54">
 <italic>Favipiravir</italic> was approved for the treatment of COVID-19 in China in March 2020. In addition, patients with COVID-19 infection are being recruited for randomized trials to evaluate the efficacy of favipiravir plus interferon-Î± (ChiCTR2000029600) and favipiravir plus baloxavir marboxil (ChiCTR2000029544).
</p>
